We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
AARTIDRUGS.NSE

Price
405.00
Stock movement down
-2.85 (-0.70%)
Company name
Aarti Drugs Limited
Exchange
(NSE
,
Currency
INR
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Market cap
36.96B
Ent value
48.33B
Price/Sales
1.49
Price/Book
2.52
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
18.57
Forward P/E
18.33
PEG
-
EPS growth
3.88%
1 year return
-11.02%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2025-12-06

DIVIDENDS

AARTIDRUGS.NSE does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E18.57
Price to OCF9.31
Price to FCF29.46
Price to EBITDA10.42
EV to EBITDA13.63

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales1.49
Price to Book2.52
EV to Sales1.95

FINANCIALS

Per share

Loading...
Per share data
Current share count91.27M
EPS (TTM)-
FCF per share (TTM)-

Income statement

Loading...
Income statement data
Revenue (TTM)-
Gross profit (TTM)-
Operating income (TTM)-
Net income (TTM)-
EPS (TTM)-
EPS (1y forward)22.10

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash66.50M
Net receivables7.20B
Total current assets13.12B
Goodwill0.00
Intangible assets99.10M
Property, plant and equipment12.48B
Total assets26.12B
Accounts payable3.77B
Short/Current long term debt5.73B
Total current liabilities7.83B
Total liabilities11.44B
Shareholder's equity14.69B
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-
Capital expenditures (TTM)-
Free cash flow (TTM)-
Dividends paid (TTM)-

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-
Return on Invested Capital-
Cash Return on Invested Capital-

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open410.00
Daily high410.00
Daily low398.50
Daily Volume152K
All-time high1011.85
1y analyst estimate597.00
Beta0.15
EPS (TTM)-
Dividend per share0.00
Ex-div date4 Feb 2025
Next earnings date27 Jan 2026

Downside potential

Loading...
Downside potential data
AARTIDRUGS.NSES&P500
Current price drop from All-time high-59.97%-0.25%
Highest price drop-68.20%-19.00%
Date of highest drop7 Apr 20258 Apr 2025
Avg drop from high-55.56%-2.68%
Avg time to new high-6 days
Max time to new high293 days89 days
COMPANY DETAILS
AARTIDRUGS.NSE (Aarti Drugs Limited) company logo
Marketcap
36.96B
Marketcap category
Large-cap
Description
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.
Employees
1284
Investor relations
-
CEO
Country
India
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found